NN Investment Partners Holdings N.V. lifted its holdings in shares of Zoetis Inc (NYSE:ZTS) by 2.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 246,221 shares of the company’s stock after buying an additional 5,300 shares during the quarter. NN Investment Partners Holdings N.V. owned approximately 0.05% of Zoetis worth $22,545,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Signature Estate & Investment Advisors LLC acquired a new position in Zoetis in the 3rd quarter valued at $112,000. Sun Life Financial INC increased its stake in shares of Zoetis by 604.3% in the 2nd quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock worth $112,000 after acquiring an additional 1,124 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Zoetis by 3,033.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after acquiring an additional 1,365 shares during the last quarter. Fort L.P. acquired a new stake in shares of Zoetis in the 2nd quarter worth $121,000. Finally, Lenox Wealth Advisors LLC increased its stake in shares of Zoetis by 259.4% in the 2nd quarter. Lenox Wealth Advisors LLC now owns 1,682 shares of the company’s stock worth $143,000 after acquiring an additional 1,214 shares during the last quarter. 89.75% of the stock is owned by institutional investors and hedge funds.
Shares of Zoetis stock opened at $90.18 on Wednesday. Zoetis Inc has a 12 month low of $63.25 and a 12 month high of $94.31. The stock has a market cap of $42.81 billion, a P/E ratio of 37.58, a PEG ratio of 1.74 and a beta of 1.01. The company has a debt-to-equity ratio of 2.50, a current ratio of 4.38 and a quick ratio of 2.92.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Tuesday, November 20th will be issued a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Monday, November 19th. Zoetis’s dividend payout ratio (DPR) is 20.83%.
A number of equities analysts have recently weighed in on the company. Jefferies Financial Group set a $96.00 price target on Zoetis and gave the stock a “buy” rating in a report on Friday, July 13th. Cantor Fitzgerald set a $98.00 price target on Zoetis and gave the stock a “buy” rating in a report on Friday, July 27th. Bank of America increased their price target on Zoetis from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 30th. BMO Capital Markets reiterated a “hold” rating and set a $82.00 price target on shares of Zoetis in a report on Thursday, August 2nd. Finally, Morgan Stanley increased their price target on Zoetis from $87.00 to $92.00 and gave the stock a “hold” rating in a report on Friday, August 3rd. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $92.63.
In other news, insider Catherine A. Knupp sold 46,816 shares of Zoetis stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $90.84, for a total value of $4,252,765.44. Following the completion of the transaction, the insider now owns 81,640 shares in the company, valued at approximately $7,416,177.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Roman Trawicki sold 8,266 shares of Zoetis stock in a transaction dated Tuesday, August 7th. The shares were sold at an average price of $92.53, for a total value of $764,852.98. The disclosure for this sale can be found here. Insiders have sold a total of 208,467 shares of company stock valued at $19,071,625 over the last 90 days. 0.35% of the stock is currently owned by company insiders.
Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.
Further Reading: What is the yield curve?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.